Recognising business model innovation, policy leadership and IP value creation in biotech and pharma
Register to access two of our subscriber only articles per month.
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.
@IAM_Alerts This week’s Sunday Supplement is now out, including: IBM IP chief talks strategy; Ericsson’s Vonage patent haul; Ho… https://t.co/S81XUI5Xlg Read more
@IAM_Alerts RT @TwittenByStorm: @IAM_Alerts Okay, I’ll bite.
Sometimes events come along that are bigger than IP, and we must defer to the non-IP peop… Read more
@IAM_Alerts The world has spent eight months talking about covid IP waivers when it should have been focused relentlessly on va… https://t.co/PUIYZbRg3h Read more
@IAM_Alerts The Supply Chain: once it was industry jargon, but this holiday season, it is a mainstream conversation topic. IAM'… https://t.co/8j2o6TpKzw Read more